Sugi Predict

Sugi Predict / Targets / SAP18

SAP18

Histone deacetylase complex subunit SAP18 · O00422 · SAP18 on Sugi Atlas →

1,894 patent compounds predicted against SAP18, 1,677 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Molibresib Molibresib (SCHEMBL1872390) 1.00 1/20
Molibresib Molibresib (SCHEMBL12671490) 1.00 1/20
Molibresib Molibresib (SCHEMBL12966358) 1.00 1/20
SCHEMBL9998851 SCHEMBL9998851 0.91 1/20
SCHEMBL14756282 SCHEMBL14756282 0.88 1/20
SCHEMBL15980874 SCHEMBL15980874 0.88 1/20
SCHEMBL12966165 SCHEMBL12966165 0.87 1/20
SCHEMBL14756215 SCHEMBL14756215 0.87 1/20
SCHEMBL14756339 SCHEMBL14756339 0.87 1/20
SCHEMBL15980861 SCHEMBL15980861 0.87 1/20
SCHEMBL9998825 SCHEMBL9998825 0.86 1/20
SCHEMBL15980893 SCHEMBL15980893 0.86 1/20
SCHEMBL15980803 SCHEMBL15980803 0.86 1/20
SCHEMBL1874116 SCHEMBL1874116 0.85 1/20
SCHEMBL12671221 SCHEMBL12671221 0.85 1/20
SCHEMBL14756021 SCHEMBL14756021 0.85 1/20
SCHEMBL14756240 SCHEMBL14756240 0.85 1/20
SCHEMBL14756287 SCHEMBL14756287 0.85 1/20
SCHEMBL14756335 SCHEMBL14756335 0.85 1/20
SCHEMBL14756409 SCHEMBL14756409 0.85 1/20

Clinical trials — most relevant to SAP18 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination PHASE1/PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Vorinostat in Children PHASE1/PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer PHASE2COMPLETED
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder PHASE2WITHDRAWN
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility nanUNKNOWN
Chromosome 18 Clinical Research Center nanRECRUITING
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat nanRECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport? nanUNKNOWN
Human Epilepsy Genetics--Neuronal Migration Disorders Study nanRECRUITING
Gene Expression and Inflammation in Overweight Subjects nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SAP18 binder may also engage these)

ProteinNameSimilarity
O55128 — 1.000 O55128 →
Q3T022 — 1.000 Q3T022 →
Q5RDT5 — 1.000 Q5RDT5 →
Q9VEX9 — 1.000 Q9VEX9 →
Q09250 — 0.987 Q09250 →
O64644 — 0.986 O64644 →
Q6CMF8 — 0.978 Q6CMF8 →
P0C075 — 0.977 P0C075 →
Q7SH49 — 0.976 Q7SH49 →
MAP1LC3C Microtubule-associated protein 1 light chain 3 gamma 0.975 landscape →
Q9XEB5 — 0.975 Q9XEB5 →
A2XXR7 — 0.975 A2XXR7 →
P0CO54 — 0.975 P0CO54 →
Q5QFG1 — 0.974 Q5QFG1 →
Q9W3R7 — 0.974 Q9W3R7 →
Q62625 — 0.974 Q62625 →
Q23536 — 0.974 Q23536 →
P0CO55 — 0.974 P0CO55 →
Q8IJK2 — 0.974 Q8IJK2 →
Q8S926 — 0.973 Q8S926 →
O94272 — 0.973 O94272 →
Q9VZI3 — 0.973 Q9VZI3 →
Q51MW4 — 0.973 Q51MW4 →
A3GFU8 — 0.972 A3GFU8 →
Q755X2 — 0.972 Q755X2 →
F7W503 — 0.972 F7W503 →
Q6Z1D5 — 0.972 Q6Z1D5 →
A6RA46 — 0.972 A6RA46 →
Q5BGN5 — 0.972 Q5BGN5 →
Q8IQ70 — 0.972 Q8IQ70 →